Form 4: Cardlytics Director John L. Klinck Jr. Acquires 11,000 Restricted Stock Units

Director John L. Klinck Jr. reports acquisition of 11,000 restricted stock units in Cardlytics, Inc.

Summary

• On May 20, 2025, John L. Klinck Jr., a director of Cardlytics, Inc. (CDLX), acquired 11,000 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Cardlytics common stock or its cash equivalent, at the Issuer's election.
• The RSUs will vest in full on the one-year anniversary of the grant date, provided Klinck remains a director on that date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of RSUs is a common practice and aligns the director's interests with shareholders. There are no explicit negative indicators.

Positives

• The acquisition of RSUs aligns the director's interests with those of the shareholders, incentivizing him to work towards the company's success.
• The vesting schedule encourages continued service and commitment to the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and profitability to maximize the value of the RSUs.

Key Dates

Keywords

Cardlytics, Director, RSU, Restricted Stock Units, Beneficial Ownership, Form 4, CDLX, Klinck